

## Octreotide

<b>Potential SALAD</b>	
Do not confuse with Sandostatin LAR® which is a depot octreotide preparation that can only be given IM	
<b>Form</b>	50 microgram per 1mL ampoule 100 microgram per 1 mL ampoule 500microgram per 1mL ampoule
<b>Reconstitution</b>	Already in solution
<b>Compatibility &amp; Stability</b>	Sodium Chloride 0.9%
<b>Administration</b>	<p><b><u>SC Injection (preferred route)</u></b> Allow the injection to reach room temperature before administration. Withdraw the required dose, and give by SC injection.</p> <p><b><u>IV Injection (for use only when rapid response required)</u></b> Dilute each 1mL octreotide with 1 - 9mL sodium chloride 0.9%. Give slowly over 3 - 5 minutes.</p> <p><b><u>Intermittent IV Infusion (unlicensed)</u></b> Preferably administer via a central venous access device to avoid potential venous irritation. If given peripherally, choose a large vein and monitor the injection site closely. Add required dose to 50 - 100mL infusion fluid and administer over 15 - 30 minutes or at a rate of 25-50microgram/hour, depending on indication.</p> <p><b><u>Continuous IV Infusion (bleeding varices)</u></b> Preferably administer via a central venous access device to avoid potential venous irritation. If given peripherally, choose a large vein and monitor the injection site closely. Add 500 microgram to 50mL infusion fluid (giving a solution of 10microgram/mL) and administer at a rate of 25 – 50 microgram/hour.</p>
<b>Monitoring</b>	<ul style="list-style-type: none"> <li>• ECG and blood pressure monitoring required for IV doses.</li> <li>• Monitor blood glucose levels.</li> </ul>
<b>Extravasation</b>	<ul style="list-style-type: none"> <li>• Local discomfort may be reduced by allowing the solution to reach room temperature before injection, or by injecting a smaller volume using a more concentrated solution</li> <li>• Extravasation is likely to cause tissue damage due to low pH.</li> </ul>
<b>Additional Information</b>	<ul style="list-style-type: none"> <li>• Give all doses between meals or before bedtime to reduce flatulence, abdominal pain and bloating.</li> </ul>

**Information provided relates to Sandostatin® manufactured by Novartis.**

*This information has been summarised to act as a guide for those administering IV medication. The monograph should be used in conjunction with the drug data sheet and BNF for information on dose, adverse effects, cautions and contra-indications. Further information is available from Pharmacy on 22146 or 22542*